Navigation Links
ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis
Date:10/17/2011

MOUNTAIN VIEW, Calif., Oct. 17, 2011 /PRNewswire/ -- ChemoCentryx, Inc., today announced the initiation of a Phase II clinical trial for CCX168, an orally-administered small molecule for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), a disease which can lead to renal and pulmonary failure.  CCX168 specifically targets the C5a receptor (C5aR), a potent pro-inflammatory mediator that is involved in AAV as well as several other autoimmune diseases.  This randomized, double-blind, placebo-controlled trial will evaluate the safety and tolerability of CCX168 in patients with ANCA-associated renal vasculitis while assessing the potential for reducing or eliminating the use of corticosteroids in these patients.  

"Having advanced six orally active drugs into the clinic, we believe that we have successfully demonstrated the capabilities of our drug discovery platform and have shown the promise of blocking specific chemokines and chemoattractant cytokines in the treatment of autoimmune and inflammatory diseases," stated Thomas J. Schall, Ph.D., President and CEO, ChemoCentryx.  "Today's announcement is another example of how we are harnessing our drug discovery and development capabilities to address inflammatory and autoimmune diseases that currently have inadequate treatment options."

About C5aR and CCX168

The complement system consists of a set of proteins that regulate certain types of inflammatory responses. Fragments of complement proteins, such as the chemoattractant complement fragment known as C5a, work to recruit immune system cells, including neutrophils, to sites of inflammation by means of its receptor (C5aR). This system is active in many diseases, thus making C5aR an attractive target for human therapeutics. Given molecular structure similarities between the C5aR and chemokine receptors, ChemoCentryx researchers successfully applied the Company's proprietary drug disco
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
3. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
4. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
5. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
6. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
7. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
8. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
9. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
10. ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Treating Patients with Crohns Disease at the United European Gastroenterology Federation (UEGW) Meeting
11. ChemoCentryx Reports Positive Phase I Results for CCX168, a Novel C5aR Antagonist, at the Annual American College of Rheumatology Meeting (ACR)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014  IGI Laboratories, Inc. (NYSE ... closing of its offering of $125 million aggregate principal ... "Notes").  The Notes were offered and sold only to ... Securities Act of 1933, as amended (the "Securities Act"). ... rate of 3.75% per year, payable semiannually in arrears ...
(Date:12/15/2014)... December 15, 2014 ... 19. und 20. Februar sind alle akkreditierten ... MEDICINE ECOSYSTEM PARTNER PROGRAMM ™ 2015 in ... Diese Tagung soll dazu beitragen, ... geben, die neue profitablen Unternehmensdienstleistungen, die für ...
(Date:12/15/2014)... --Research and Markets , ... announced the addition of the "Cardiac Guidewires - ... offering. Global Guidewires sector is projected to reach ... accounts for nearly 35% (2015) of the ... approximately 25% (2018). Asia-Pacific is ...
Breaking Medicine Technology:IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 2Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 3Cardiac Guidewires - Global Trends, Estimates and Forecasts, 2012-2018 4
... CARLOS, Calif, April 11, 2007 /PRNewswire-FirstCall/ --,Nuvelo, ... from a study,of NU206 (R-Spondin1), a secreted ... acts as a specific and potent,stimulator of ... damaged in patients with inflammatory bowel,conditions, including ...
... 10, 2007 - The two most,prevalent forms of ... share a common cause, according to researchers at,Stanford ... network in the brain, may also be associated ... very different, the,end result for the brain seems ...
Cached Medicine Technology:Nuvelo Announces Publication of NU206 Study Results in,Gastroenterology 2Nuvelo Announces Publication of NU206 Study Results in,Gastroenterology 3Nuvelo Announces Publication of NU206 Study Results in,Gastroenterology 4Fragile X, Down Syndromes Linked to Faulty Brain Communication,Stanford Researcher Finds 2Fragile X, Down Syndromes Linked to Faulty Brain Communication,Stanford Researcher Finds 3Fragile X, Down Syndromes Linked to Faulty Brain Communication,Stanford Researcher Finds 4
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... example of the Bush Administration promoting, politics over a sound health ... oversight of the federal family planning program and the health of ... ... National Abortion,Federation (NAF) denounces the appointment of Dr. Susan Orr as ...
... 40|86 Strategic Income,Fund (NYSE: CFD ) declared a ... holders of record at the close of business on ... closed-end investment management,company. The Fund,s primary investment objective is ... prospectus, the Fund intends to,distribute substantially all of its ...
... State Senate,Committee passed legislation today (October 17) that would enable,motorcyclists ... bid to rid riders of their helmets, special interest groups ... motorcyclists,can buy their way out of a helmet. The ... Senate in the near,future. The bill was passed by the ...
... standard treatment best against the facial paralysis, study finds , , ... is no better at easing a form of facial paralysis ... , The fact that acyclovir may not be a new, ... say, but on the other hand, many people afflicted with ...
... defect exists in men, it could lead to new treatments, ... defect in a gene that,s essential for the formation of ... of sperm from being able to penetrate an egg. , ... at Chapel Hill, was based on research with mice. But ...
... Governors,University (http://www.wgu.edu ) is now offering its ... managers and nurse educators. These,scholarships are designed to ... become educators, managers, and leaders in various healthcare,settings. ... and,M.S. in Nursing-Leadership and Management degree programs., ...
Cached Medicine News:Health News:National Abortion Federation Denounces the Appointment of Dr. Orr to Oversee Federal Family Planning Funds 2Health News:Michigan Senate Committee Votes in Favor of 'Opt-Out' Option for State's Helmet Law; AAA Says Deaths and Injuries Will Increase 2Health News:Antiviral Won't Improve Bell's Palsy Outcome 2Health News:Gene Mutation Key to Infertility in Male Mice 2Health News:Nursing Scholarships Offered by Western Governors University for Master's Degree Programs 2
Complete calibration kits are available for both pH and manometry systems....
... formulated buffers are available from ... antimony catheters. All buffers are ... internal or external reference, single ... are available in 250ml bottle ...
... formulated buffers are available from ... antimony catheters. All buffers are ... internal or external reference, single ... are available in 250ml bottle ...
Flexilog custom medical carts are configured to suite the requirements of FLEXILOG motility system users. With locking wheels and storage drawers, our carts are suitable for any care provider in any ...
Medicine Products: